Skip to content

Survival With Patients Treated With Salivary Gland Cancer

Prognostic Factors for Survival of Patients With Salivary Gland Malignancies

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05390294
Enrollment
250
Registered
2022-05-25
Start date
2022-01-01
Completion date
2022-04-30
Last updated
2022-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Salivary Gland Cancer, Salivary Gland Neoplasms

Keywords

Salivary gland cancer, Survival, Prognostic factors

Brief summary

Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival

Detailed description

The retrospective study enrolled medical charts of the patients treated due to salivaly gland cancers in the Clinic for maxillofacial surgery at Clinical center of Vojvodina in the period of 1. January 1996. to 31. December 2021. Patients demographics, type of the tumor, localization, TNM status and patohystological parameters were evaluated for patients survival and disease free periods

Interventions

PROCEDURESurgical intervention with or without postoperative adjuvant therapy

Surgical intervention with or without postoperative adjuvant therapy

Sponsors

Clinical Center of Vojvodina
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Patients with salivary gland malignancies treted in the Clinic for maxillofacial surgery

Exclusion criteria

Incomplete medical data Patients with metastatic tumord of salivary gland Patients with recurrent malignancies of salivary glands sent from other clinics

Design outcomes

Primary

MeasureTime frameDescription
Patients survivalThrough study completion, an average of 1 yearSurvival of patients treated due to SGC during observation period of minimum 2 years

Countries

Serbia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026